The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels

The wide-spread use of drug-eluting stents (DES) has evolved as standard of care in de novo
lesions. The proposed study will evaluate the safety and effectiveness of PROMUS Element for
the treatment of de novo atherosclerotic lesions in native coronary arteries. The study
design is consistent with the draft guidance for industry titled, "Coronary Drug-Eluting
Stents - Nonclinical and Clinical Studies" (March 2008).

During the trial, thienopyridines must be administered according to the 2007 American College
of Cardiology (ACC)/American Heart Association (AHA)/Society for Cardiovascular Angiography
and Interventions (SCAI) guidelines, which recommended that clopidogrel (75 mg daily) or
ticlopidine (250 mg twice daily) be prescribed after stent implantation for at least 6 months
in all patients, and for at least 12 months in patients who are not at high risk of bleeding.
For sites in the United States, the use of prasugrel is not allowed as part of the PLATINUM
Clinical Trial. For sites in other countries, prasugrel may be prescribed according to its
approved dosing in countries in which it is available. For patients taking aspirin daily a
loading dose is recommended; for patients who have not been taking aspirin daily, aspirin
must be administered as a loading dose. Patients continue to take aspirin indefinitely to
reduce the risk of thrombosis.

This PLATINUM Small Vessel study is a sub-trial associated with the PLATINUM Workhorse
Randomized Controlled Trial, which is registered under NCT00823212.

Inclusion Criteria:

- Patient must be at least 18 years of age

- Patient (or legal guardian) understands study requirements and treatment procedures
and provides written informed consent before any study-specific tests or procedures
are performed

- For patients less than 20 years of age enrolled at a Japanese site, patient and
patient's legal representative must provide written informed consent before any
study-specific tests or procedures are performed

- Patient is eligible for percutaneous coronary intervention (PCI)

- Patient has documented stable angina pectoris or documented silent ischemia; or
unstable angina pectoris

- Patient is an acceptable candidate for coronary artery bypass grafting (CABG)

- Patient has a left ventricular ejection fraction (LVEF) >=30% as measured within 30
days prior to enrollment

- Patient is willing to comply with all protocol-required follow-up evaluations

Angiographic Inclusion Criteria (visual estimate):

- Target lesion must be a de novo lesion located in a native coronary artery with a
visually estimated reference vessel diameter ≥2.25 mm and <2.5 mm. Target lesion length
must measure ≤28 mm by visual estimate. Target lesion must be located in a major coronary
artery or branch with visually estimated stenosis ≥50% and <100% with Thrombolysis In
Myocardial Infarction (TIMI) flow >1.

Exclusion Criteria:

- Patient has clinical symptoms and/or electrocardiogram (ECG) changes consistent with
acute myocardial infarction (MI)

- Patient has had a known diagnosis of recent MI (ie, within 72 hours prior to index
procedure) and has elevated enzymes at time of index procedure as follows.

- Patients are excluded if any of the following criteria are met at time of the
index procedure.

- If creatine kinase-myoglobin band (CK-MB) >2× upper limit of normal (ULN),
the patient is excluded regardless of CK Total.

- If CK-MB is 1-2× ULN, the patient is excluded if the CK Total is >2× ULN.

- If CK Total/CK MB are not used and Troponin is, patients are excluded if the
following criterion is met at time of index procedure.

- Troponin >1× ULN with at least one of the following.

- Patient has ischemic symptoms and ECG changes indicative of ongoing ischemia (eg,
>1 mm ST segment elevation or depression in consecutive leads or new left bundle
branch block [LBBB]);

- Development of pathological Q waves in the ECG; or

- Imaging evidence of new loss of viable myocardium or new regional wall motion
abnormality.

Note: For patients with unstable angina or patients who have had a recent MI, CK Total/CK
MB (or Troponin if CK Total/CK MB are not used) must be documented prior to
enrolling/randomizing the patient.

- Patient has received an organ transplant or is on a waiting list for an organ
transplant

- Patient is receiving or scheduled to receive chemotherapy within 30 days before or
after index procedure

- Patient is receiving oral or intravenous immunosuppressive therapy (ie, inhaled
steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune
disease (eg, human immunodeficiency virus, systemic lupus erythematosus, but not
including diabetes mellitus)

- Patient is receiving chronic (>=72 hours) anticoagulation therapy (eg, heparin,
coumadin) for indications other than acute coronary syndrome

- Patient has platelet count <100,000 cells/mm3 or >700,000 cells/mm3

- Patient has white blood cell (WBC) count <3,000 cells/mm3

- Patient has documented or suspected liver disease, including laboratory evidence of
hepatitis

- Patient is on dialysis or has known renal insufficiency (ie, estimated creatinine
clearance <50 ml/min by the Cockcroft Gault formula, or [(140-age)*lean body weight
(in kg)]/[plasma creatinine (mg/dl)*72])

- Patient has history of bleeding diathesis or coagulopathy or will refuse blood
transfusions

- Patient has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA)
within past 6 months, or has any permanent neurologic defect that may cause
non-compliance with the protocol

- Target vessel(s) or side branch has been treated with any type of PCI (eg, balloon
angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to index
procedure

- Target vessel(s) has been treated within 10 mm proximal or distal to target lesion (by
visual estimate) with any type of PCI (eg, balloon angioplasty, stent, cutting
balloon, atherectomy) at any time prior to index procedure

- Non-target vessel or side branch has been treated with any type of PCI (eg, balloon
angioplasty, stent, cutting balloon, atherectomy) within 24 hours prior to index
procedure

- Planned or actual target vessel(s) treatment with an unapproved device, directional or
rotational coronary atherectomy, laser, cutting balloon, or transluminal extraction
catheter immediately prior to stent placement

- Planned PCI or CABG after index procedure

- Patient previously treated at any time with coronary intravascular brachytherapy

- Patient has a known allergy to the study stent system or protocol-required concomitant
medications (eg, stainless steel, platinum, cobalt, chromium, nickel, tungsten,
acrylic, fluoropolymers, everolimus, thienopyridines, aspirin, contrast) that cannot
be adequately premedicated

- Patient has active peptic ulcer or active gastrointestinal (GI) bleeding

- Patient has one of the following.

- Other serious medical illness (eg, cancer, congestive heart failure) that may
reduce life expectancy to less than 24 months

- Current problems with substance abuse (eg, alcohol, cocaine, heroin, etc.)

- Planned procedure that may cause non-compliance with protocol or confound data
interpretation

- Patient is participating in another investigational drug or device clinical trial that
has not reached its primary endpoint

- Patient intends to participate in another investigational drug or device clinical
trial within 12 months after index procedure

- Patient with known intention to procreate within 12 months after index procedure
(Women of child-bearing potential who are sexually active must agree to use a reliable
method of contraception from the time of screening through 12 months after the index
procedure.)

- Patient is a woman who is pregnant or nursing (A pregnancy test must be performed
within 7 days prior to the index procedure in women of child-bearing potential)

- Patient has more than 2 target lesions, or more than 1 target lesion and 1 non-target
lesion, which will be treated during the index procedure